Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141415 | 0.92 | CHRM4 (0.54) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL7140154 | 0.92 | HTT (0.58) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL7142247 | 0.91 | NPSR1 (0.56) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL7141686 | 0.86 | CHRM2 (0.61) | CHRM2CHRM3OPRM1SIGMAR1MEN1 | |
| SCHEMBL7149783 | 0.85 | ACHE (0.54) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL7149576 | 0.85 | BCHE (0.54) | HTR2ACHRM2ACHE | |
| SCHEMBL9785741 | 0.85 | OPRM1 (0.57) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9785675 | 0.84 | OPRM1 (0.56) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL14997384 | 0.83 | HTR2A (0.61) | HTR2ACHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL7166030 | 0.82 | CHRM2 (0.57) | CHRM2CHRM3OPRM1SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | claimed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | claimed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | claimed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | HTR2A 45/4885CHRM2 320/4885CHRM3 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.